RenovoRx RNXT
NASDAQ RNXT
$1.32 +0.00 (+0.00%)
At close: Aug 21, 2026 · 4:00 PM EDT

RenovoRx (RNXT) Depreciation & Amortization (CF) (2025 - 2026)

RenovoRx (RNXT) posted Depreciation & Amortization (CF) of $1000.0 for Q1 2026, down 99.9% sequentially from $1.0 million in Q3 2025, and little changed YoY from $1000.0 in Q1 2025.

RenovoRx (RNXT) Depreciation & Amortization (CF) (2025 - 2026) Analysis & Trends

RenovoRx has reported Depreciation & Amortization (CF) for 2 years, with the latest figure at $1000.0 in Q1 2026.

  • Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 200000.0% YoY) and the FY2025 annual result came in at $2.0 million, changed N/A from the prior year.
  • Depreciation & Amortization (CF) slipped to $1000.0 in Q1 2026 per RNXT's latest filing, from $1.0 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $1.0 million in Q2 2025 and troughed at $1000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 56.50 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 123.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 40.52 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 191.83 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 RenovoRx 62.20 Mn 62.20 Mn 766,000.00 -

Historic Data

Download Data
DateValue
Jun 30, 2026 5,000.00
Jun 30, 2026 5,000.00
Mar 31, 2026 1,000.00
Mar 31, 2026 1,000.00
Sep 30, 2025 1.00 Mn
Sep 30, 2025 1.00 Mn
Jun 30, 2025 1.00 Mn
Jun 30, 2025 1.00 Mn
Mar 31, 2025 1,000.00
Mar 31, 2025 1,000.00